Molecular modeling of the human vasopressin V2 receptor/agonist complex

The V2 vasopressin renal receptor (V2R), which controls antidiuresis in mammals, is a member of the large family of heptahelical transmembrane (7TM) G protein-coupled receptors (GPCRs). Using the automated GPCR modeling facility available via Internet (http://expasy.hcuge.ch/swissmod/SWISS-MODEL.html) for construction of the 7TM domain in accord with the bovine rhodopsin (RD) footprint, and the SYBYL software for addition of the intra- and extracellular domains, the human V2R was modeled. The structure was further refined and its conformational variability tested by the use of a version of the Constrained Simulated Annealing (CSA) protocol developed in this laboratory. An inspection of the resulting structure reveals that the V2R (likewise any GPCR modeled this way) is much thicker and accordingly forms a more spacious TM cavity than most of the hitherto modeled GPCR constructs do, typically based on the structure of bacteriorhodopsin (BRD). Moreover, in this model the 7TM helices are arranged differently than they are in any BRD-based model. Thus, the topology and geometry of the TM cavity, potentially capable of receiving ligands, is in this model quite different than it is in the earlier models. In the subsequent step, two ligands, the native [arginine8]vasopressin (AVP) and the selective agonist [d-arginine8]vasopressin (DAVP) were inserted, each in two topologically non-equivalent ways, into the TM cavity and the resulting structures were equilibrated and their conformational variabilities tested using CSA as above. The best docking was selected and justified upon consideration of ligand-receptor interactions and structure-activity data. Finally, the amino acid residues were indicated, mainly in TM helices 3-7, as potentially important in both AVP and DAVP docking. Among those Cys112, Val115-Lys116, Gln119, Met123 in helix 3; Glu174 in helix 4; Val206, Ala210, Val213-Phe214 in helix 5; Trp284, Phe287-Phe288, Gln291 in helix 6; and Phe307, Leu310, Ala314 and Asn317 in helix 7 appeared to be the most important ones. Many of these residues are invariant for either the GPCR superfamily or the neurophyseal (vasopressin V2R, V1aR and V1bR and oxytocin OR) subfamily of receptors. Moreover, some of the equivalent residues in V1aR have already been found critical for the ligand affinity [Mouillac et al., J. Biol. Chem, 270 (1995) 25771].

[1]  E. Kojro,et al.  Separate Agonist and Peptide Antagonist Binding Sites of the Oxytocin Receptor Defined by Their Transfer into the V2 Vasopressin Receptor* , 1996, The Journal of Biological Chemistry.

[2]  A. Scheer,et al.  Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation. , 1996, The EMBO journal.

[3]  C. Levinthal,et al.  Predicting antibody hypervariable loop conformation. I. Ensembles of random conformations for ringlike structures , 1987, Biopolymers.

[4]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[5]  J. Baldwin The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[6]  F Guarnieri,et al.  A refined model of the thyrotropin-releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. , 1996, Biochemistry.

[7]  C. Strader,et al.  Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.

[8]  R Henderson,et al.  Electron-crystallographic refinement of the structure of bacteriorhodopsin. , 1996, Journal of molecular biology.

[9]  G. Flouret,et al.  Neurohypophyseal hormone-responsive renal adenylate cyclase. II. Relationship between hormonal occupancy of neurohypophyseal hormone receptor sites and adenylate cyclase activation. , 1978, The Journal of biological chemistry.

[10]  P. Kraulis A program to produce both detailed and schematic plots of protein structures , 1991 .

[11]  Gebhard F. X. Schertler,et al.  Projection structure of rhodopsin , 1993, Nature.

[12]  T. Sugimoto,et al.  Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. , 1994, The Journal of biological chemistry.

[13]  S. H. Buck The Tachykinin Receptors , 1994, The Receptors.

[14]  T R Stouch,et al.  Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors. , 1995, Journal of medicinal chemistry.

[15]  T. Blundell,et al.  Crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding. , 1988, Science.

[16]  P Herzyk,et al.  Automated method for modeling seven-helix transmembrane receptors from experimental data. , 1995, Biophysical journal.

[17]  K Prendergast,et al.  Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. , 1994, Chemistry & biology.

[18]  X. Bertagna,et al.  Cloning and characterization of the human V3 pituitary vasopressin receptor , 1994, FEBS letters.

[19]  J. Wess,et al.  Different Single Receptor Domains Determine the Distinct G Protein Coupling Profiles of Members of the Vasopressin Receptor Family (*) , 1996, The Journal of Biological Chemistry.

[20]  F. Fahrenholz,et al.  An extracellular residue determines the agonist specificity of V2 vasopressin receptors , 1995, FEBS letters.

[21]  J. Shine,et al.  Protein-coupled Receptors , 1996 .

[22]  J Hoflack,et al.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. , 1995, The EMBO journal.

[23]  E. Kojro,et al.  Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor. , 1993, Biochemistry.

[24]  R. Henderson,et al.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.

[25]  V. Hruby,et al.  Conformational and structural considerations in oxytocin-receptor binding and biological activity. , 1990, Annual review of pharmacology and toxicology.

[26]  F. László,et al.  Pharmacology and clinical perspectives of vasopressin antagonists. , 1991, Pharmacological reviews.

[27]  J Hoflack,et al.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.

[28]  F Guarnieri,et al.  A refined model of the thyrotropin-releasing hormone (TRH) receptor binding pocket. Novel mixed mode Monte Carlo/stochastic dynamics simulations of the complex between TRH and TRH receptor. , 1996, Biochemistry.

[29]  C. Levinthal,et al.  Predicting antibody hypervariable loop conformations II: Minimization and molecular dynamics studies of MCPC603 from many randomly generated loop conformations , 1986, Proteins.

[30]  J. Shine,et al.  G protein-coupled receptors , 1992, Current Biology.

[31]  J Hoflack,et al.  The Binding Site of Neuropeptide Vasopressin V1a Receptor , 1995, The Journal of Biological Chemistry.